In short
Maralixibat Chloride is an investigational drug currently being studied in clinical trials for its potential to treat cholestatic pruritus, a condition characterized by severe itching associated with liver diseases. This article explores the ongoing research into this medication, its potential benefits, and what patients should know about participating in these trials.
At a glance
- Drug Name
- Maralixibat Chloride
- Drug Type
- Ileal bile acid transporter (IBAT) inhibitor
- Condition Studied
- Cholestatic Pruritus
- Main Objective
- Evaluate efficacy in reducing pruritus severity
- Study Design
- Randomized, Double-Blind, Placebo-Controlled Phase 3 Study
- Primary Endpoint
- Change in ItchRO(Obs) severity score from baseline through Weeks 13-20
- Key Secondary Endpoints
- Change in total serum bile acid levels, percentage of days with pruritus improvement
- Participant Age
- ≥6 months
- Treatment Duration
- Up to 40 weeks
- Dosage Form
- Oral Solution
What is Maralixibat Chloride?
Maralixibat Chloride is a medication currently being studied for the treatment of cholestatic pruritus, which is severe itching associated with certain liver conditions. It is taken as an oral solution, meaning it's a liquid medicine that you drink.
What is Cholestatic Pruritus?
Cholestatic pruritus is a persistent and often severe itching that occurs in people with certain liver diseases. It happens when the flow of bile (a digestive fluid produced by the liver) is reduced or blocked, leading to a buildup of substances in the blood that can cause intense itching.
How Does Maralixibat Work?
Maralixibat Chloride is what's known as an ileal bile acid transporter (IBAT) inhibitor. This means it works by blocking a specific transporter in the intestines that normally helps to recycle bile acids back into the body. By doing this, Maralixibat helps to reduce the levels of bile acids in the blood, which may help to relieve the itching associated with cholestatic liver diseases.
Current Clinical Trial
A clinical trial is currently underway to test how well Maralixibat works for treating cholestatic pruritus. This is a Phase 3 study, which means it's in an advanced stage of testing. The study is: Randomized: Participants are randomly assigned to either receive Maralixibat or a placebo (a substance with no active ingredients). Double-blind: Neither the participants nor the researchers know who is receiving the real medication and who is receiving the placebo. Placebo-controlled: Some participants receive a placebo to compare the effects with those who receive the actual medication. This design helps ensure that the results of the study are as accurate and unbiased as possible.
Who Can Participate in the Study?
The study is looking for participants who: Are at least 6 months old Have been diagnosed with a cholestatic liver disease that causes itching Have had itching for more than 90 days Have higher than normal levels of bile acids in their blood There are also some reasons why a person might not be able to participate, such as having certain other medical conditions or taking certain medications.
What to Expect During the Study
If you participate in the study: You'll need to take the study medication (or placebo) daily for 40 weeks. You'll be asked to keep track of your itching using a special tool called the ItchRO (Itch Reported Outcome). You'll have regular check-ups and blood tests to monitor your health and the effects of the medication. The researchers will be looking at how much your itching improves and how the medication affects the levels of bile acids in your blood.
Potential Benefits of Maralixibat
While the study is still ongoing and we don't know the final results yet, the researchers hope that Maralixibat will: Reduce the severity of itching in people with cholestatic liver diseases Lower the levels of bile acids in the blood Improve quality of life for people suffering from chronic itching due to liver disease It's important to remember that these potential benefits are still being studied, and not all participants may experience them.